Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
Supernus Pharmaceuticals, Inc. (SUPN) had Non-Operating Income/Expense of $2.28M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$192.10M |
|
$-45.12M |
|
$18.96M |
|
$173.14M |
|
$252.33M |
|
$-60.23M |
|
|
Non-Operating Income/Expense |
$2.28M |
$-57.95M |
|
$-57.95M |
|
$-45.12M |
|
$-45.12M |
|
$-45.12M |
|
$-45.12M |
|
$-60.23M |
|
$-36.35M |
|
56.55M |
|
56.55M |
|
$-0.80 |
|
$-0.80 |
|
| Balance Sheet Financials | |
$593.89M |
|
$10.63M |
|
$825.86M |
|
$1.42B |
|
$330.63M |
|
-- |
|
$39.46M |
|
$370.09M |
|
$1.05B |
|
$307.11M |
|
$1.05B |
|
57.12M |
|
| Cash Flow Statement Financials | |
$27.47M |
|
$55.42M |
|
$0.60M |
|
$69.33M |
|
$152.82M |
|
$83.49M |
|
$23.40M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.80 |
|
-- |
|
-- |
|
-- |
|
-- |
|
90.13% |
|
-31.35% |
|
-31.35% |
|
-- |
|
-30.17% |
|
-23.49% |
|
$26.56M |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
0.24 |
|
1.12 |
|
80.23 |
|
-4.30% |
|
-14.69% |
|
-3.18% |
|
-4.30% |
|
$18.38 |
|
$0.47 |
|
$0.49 |
|